Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 96

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 96
---
 adequately invest in artificial intelligence development as well as new technologies to keep pace with the rapid rate of change in our markets and meet customer needs. Our continued growth also depends on our ability to successfully develop and introduce new products and services on a timely basis, as well as our ability to establish and maintain adequate commercial, distribution, sales and laboratory testing capabilities. We need to be able to differentiate our products from well -established, large competitors in the market and start to prepare products for international markets in multiple aspects. If we are unable to do so, our operations may be adversely affected. For at least the next twelve months, our ability to generate revenues will depend substantially on the commercial success of our tests and services. There can be no assurance that we will develop or commercialize any other products or services that will generate significant revenue, or that we will be able to do so on a timely basis. The commercial success of our tests and our ability to generate revenues will depend on a variety of factors, including acceptance in the medical community, patient acceptance and demand, patient compliance with orders for our tests by healthcare providers, and patient adherence to recommendations regarding periodic re -testing, successful sales, marketing, and educational programs, including successful direct -to -consumermarketing such as television advertising and social media, the number of patients screened, the number of women diagnosed, the amount and nature of competition from other products and procedures, maintaining regulatory approvals to legally market, the ease of use of our ordering process for healthcare providers, maintaining and defending patent protection for the intellectual property relevant to our products and services, and our ability to establish and maintain adequate commercial, distribution, sales and laboratory testing capabilities. If we are unable to continue to grow sales of our tests in Argentina and abroad, are unable to build a business beyond Argentina or are delayed or limited in doing so, our business prospects, financial condition and results of operations would be adversely affected. Additionally, we are devoting significant resources to the development of our new products. The successful commercialization of these tests will also be subject to the factors listed above, among others. If we are unable to successfully commercialize these new products, our business, results of operations, financial condition and growth prospects may be adversely affected. We depend on CIBIC, one of our indirect shareholders, for a substantial part of our revenues, and if the Commercialization Agreement is terminated, our business and results of operations would be materially adversely affected. On January 3, 2017, Heritas Argentina entered into a commercialization agreement, as